Natalie E. Williams

Natalie E. Williams

Auto-generated profile, based on publicly available information

Natalie E. Williams

Department of Surgery UT Southwestern Medical Center Dallas Texas USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Cancer Research
Verified
Journal Article
Open access
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor. Significance: Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.

15 August 2025
Verified
Other
Open access
PDF file
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
Inhibition of TGFb reduces IL-6 expression and STAT3 activation in PDAC

15 August 2025
Verified
Other
Open access
PDF file
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
TGFb gene family LOH and SMAD mosaicism

15 August 2025
Verified
Other
Open access
PDF file
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
Inhibition of TGFb reduces survival in mice bearing 6620c1 orthotopic tumors

15 August 2025
Verified
Other
Open access
PDF file
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
Loss of Smad4 alters the secretome of pancreatic cancer cells

15 August 2025
Verified
Other
Open access
GMGilbert Z. Murimwa
Gilbert Z. Murimwa
NWNatalie E. Williams
Natalie E. Williams
DADina Alzhanova
Dina Alzhanova
AMAmir Mohammadi
Amir Mohammadi
JWJill M. Westcott
Jill M. Westcott
Rolf BrekkenRolf Brekken
Rolf Brekken
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the therapies have gained FDA approval. Nevertheless, TGFβ blockade may hold promise for a subset of cancers with nonfunctional TGFβ signaling. More than 25% of pancreatic cancers carry mutations in SMAD4, a key component of canonical TGFβ signaling. In this study, we investigated the potential for stratifying patients based on SMAD4 mutational status to identify tumors susceptible to TGFβ inhibition. Analysis of SMAD4 expression in human pancreatic tumors revealed that SMAD4 mutation or loss is associated with worse disease-free survival. Intriguingly, intratumoral SMAD4 expression displayed heterogeneity among human pancreatic cancer samples. SMAD4-deficient genetically engineered mouse models and orthotopic SMAD4 knockout tumor models exhibited reduced survival, increased metastasis, and alterations in the tumor microenvironment compared with SMAD4 wild-type controls, consistent with gene and protein expression changes in the absence of functional SMAD4. Importantly, treating mice bearing SMAD4-deficient tumors with a blocking TGFβ antibody reduced tumor weight and improved survival. These findings suggest that genomic stratification by TGFβ axis alterations, such as SMAD4 mutations, may be a promising approach to identifying patients likely to benefit from a TGFβ inhibitor.Significance:Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.